Scientists in Cork have identified a novel therapy for the bacteria which cause infections in cystic fibrosis patients.
The research was carried out the Alimentary Pharmabiotic Centre [APC], a Science Foundation Ireland funded research centre based in UCC, Teagasc Moorepark Research Centre and CIT.
Cystic fibrosis is a genetic disease which is particularly common in Ireland and results in a build-up of mucous in the lungs of affected individuals. Very often this mucous can become contaminated with Pseudomonas aeruginosa. While the care of cystic fibrosis patients has improved dramatically in recent years, these infections remain a very difficult problem to resolve. They are difficult to treat with normal antibiotics which cannot easily gain access to the bacteria in the lungs. This usually means the patient has to take antibiotics on a continual basis, which can lead to the development of antibiotic resistant superbugs.
Click "source" to read more.
mBio - "Bacteriophages ϕMR299-2 and ϕNH-4 Can Eliminate Pseudomonas aeruginosa in the Murine Lung and on Cystic Fibrosis Lung Airway Cells" (http://mbio.asm.org/content/3/2/e00029-12.full?sid=b168da51-10d7-40bf-915c-6e5d29de2770)